Jordan D. Berlin

Jordan D. Berlin's AcademicInfluence.com Rankings

Jordan D. Berlin

Philosophy

#8933

World Rank

#12414

Historical Rank

Logic

#5939

World Rank

#7402

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jordan D. Berlin's Degrees

Doctorate Medicine Johns Hopkins University
PhD Biomedical Sciences Johns Hopkins University

Why Is Jordan D. Berlin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jordan D. Berlin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (2004) (8460)
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors (2017) (1823)
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children (2018) (1570)
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers (2012) (1550)
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. (2008) (1030)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. (2002) (738)
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. (2005) (697)
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. (2003) (646)
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab (2005) (519)
Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. (2009) (464)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. (2020) (416)
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. (2009) (399)
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. (2014) (334)
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. (2007) (309)
Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design (2013) (304)
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. (2009) (297)
Neuroendocrine tumors, version 1.2015. (2015) (291)
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016) (290)
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. (2009) (275)
Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics? (2010) (245)
Pharmacological Blockade of ASCT2-dependent Glutamine Transport Leads To Anti-tumor Efficacy in Preclinical Models (2017) (236)
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. (2018) (234)
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. (2009) (231)
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose (2008) (214)
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer (2007) (208)
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. (2018) (203)
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017) (201)
[Diagnosis and treatment of cholangiocarcinoma]. (2004) (174)
Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors (2016) (172)
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. (2008) (169)
A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer (2012) (153)
Treatment for pancreatic cancer: current therapy and continued progress. (2005) (151)
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. (2008) (150)
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. (2005) (144)
Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). (2006) (133)
Neuroendocrine and adrenal tumors, version 2.2018 featured updates to the nccn guidelines (2018) (131)
Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™ (2012) (130)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. (2017) (128)
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. (2000) (128)
Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study (2010) (127)
Treatment of metastatic pancreatic adenocarcinoma: a review. (2014) (126)
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. (2009) (117)
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. (2019) (115)
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. (2019) (104)
Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer (2010) (104)
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. (2007) (103)
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. (2014) (100)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. (2017) (99)
The epidermal growth factor receptor as a target for colorectal cancer therapy. (2005) (94)
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. (2017) (92)
Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors (2011) (86)
Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer (2006) (85)
Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) (2005) (85)
A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors (2014) (84)
The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study (2006) (83)
A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296) (2000) (82)
Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. (1996) (78)
Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial. (2021) (76)
Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). (2006) (76)
Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (2013) (76)
Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204. (2017) (70)
ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis (2004) (68)
Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study (2012) (67)
Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers (2014) (67)
Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer (2002) (64)
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. (2010) (64)
Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. (2015) (62)
Pancreatic cancer treatment and research: an international expert panel discussion. (2011) (61)
Pancreatic adenocarcinoma. (2010) (61)
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study (2018) (60)
Warfarin—5‐FU Interaction — A Consecutive Case Series (1999) (59)
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. (2001) (58)
Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. (2016) (57)
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study (2020) (57)
Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study. (2013) (57)
Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation (2011) (57)
Biliary tract cancers: understudied and poorly understood. (2015) (55)
NCCN clinical practice guidelines in oncology. Anal carcinoma. (2010) (54)
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer (2005) (54)
Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. (1997) (53)
Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum. (2008) (53)
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. (2016) (53)
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer (2019) (51)
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors (2017) (51)
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. (2017) (51)
Anal carcinoma: Clinical practice guidelines in oncology™ (2010) (51)
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. (2018) (48)
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. (2016) (47)
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors (2019) (47)
Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study (2008) (46)
Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. (2018) (45)
Aflibercept—a Decoy VEGF Receptor (2014) (45)
Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors (2011) (45)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. (2015) (45)
Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. (2019) (44)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. (2015) (44)
Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. (2013) (43)
Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement (2006) (40)
Recent advances in the treatment of pancreatic cancer (2020) (40)
Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials (2007) (38)
Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer (2010) (37)
ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. (2004) (36)
Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation (2004) (36)
Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. (2013) (35)
Current Treatment Options for Pancreatic Carcinoma (2011) (35)
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update (2021) (35)
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers (2018) (34)
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla. (2010) (34)
Exploring racial differences in outcome and treatment for metastatic colorectal cancer (2012) (33)
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas (2008) (32)
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors (1998) (32)
Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. (2017) (31)
Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298) (2004) (30)
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors (2014) (30)
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix. (2010) (29)
Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups (2004) (28)
Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. (2004) (28)
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer (2014) (28)
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer (2019) (28)
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (2018) (28)
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (2018) (27)
Phase I/Pilot Study of SU5416 (Semaxinib) in Combination With Irinotecan/Bolus 5-FU/LV (IFL) in Patients With Metastatic Colorectal Cancer (2006) (27)
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. (2016) (27)
The Past, Present, and Future of Pancreatic Cancer Clinical Trials. (2016) (25)
Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS) (2008) (25)
Targeting metastatic colorectal cancer – present and emerging treatment options (2014) (25)
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. (2020) (25)
Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. (2004) (25)
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum. (2010) (25)
Targeting vascular endothelial growth factor in colorectal cancer. (2002) (24)
Protocol for the examination of specimens from patients with carcinoma of the perihilar bile ducts. (2010) (24)
Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer (2013) (24)
Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): an Eastern Cooperative Oncology Group study. (2004) (24)
Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. (2019) (24)
Final results from cohort 1 of a phase II study of volociximab, an anti-{alpha}5{beta}1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC) (2007) (23)
3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy (2007) (23)
The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS) (2008) (23)
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group (2014) (22)
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma? (2016) (22)
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). (1998) (22)
Anti-Angiogenic Treatment of Gastrointestinal Malignancies (2005) (22)
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. (2014) (22)
Chemotherapeutic advances in pancreatic cancer (2003) (22)
Dual Blockade of the EGFR and COX-2 Pathways: A Phase II Trial of Cetuximab and Celecoxib in Patients With Chemotherapy Refractory Metastatic Colorectal Cancer (2011) (21)
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors (2015) (21)
Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. (2019) (21)
Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. (2002) (20)
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. (2007) (20)
Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials (2007) (20)
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach. (2010) (20)
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours (2018) (20)
Treatment of early-stage pancreatic cancer. (2011) (19)
The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience (2018) (19)
A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS (2017) (19)
Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma (2018) (18)
Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer (2015) (18)
Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) (18)
Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors (2008) (18)
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204) (2017) (18)
Pancreas cancer on the rise: are we up to the challenge? (2013) (18)
Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) (2016) (18)
A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors (2004) (18)
The epidermal growth factor receptor as a target for gastrointestinal cancer therapy (2004) (18)
Phase 1 study of N1,N11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma (2013) (18)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. (2016) (17)
Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. (2004) (17)
Current Concepts in the Treatment of Resectable Pancreatic Cancer (2018) (17)
Protocol for the examination of specimens from patients with carcinoma of the intrahepatic bile ducts. (2010) (17)
Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS) (2008) (17)
A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. (2020) (17)
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab. (2020) (17)
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial (2019) (16)
Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer (2019) (16)
Harnessing the Immune System in Pancreatic Cancer (2018) (16)
Use of Percutaneous Drainage to Treat Hepatic Abscess after Radiofrequency Ablation of Metastatic Pancreatic Adenocarcinoma (2004) (16)
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results (2018) (16)
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer (2020) (16)
Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis. (2010) (16)
Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. (2013) (16)
Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology (2007) (16)
Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors (2015) (15)
Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19–9 results (2008) (15)
Protocol for the examination of specimens from patients with carcinoma of the distal extrahepatic bile ducts. (2010) (14)
1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer (2020) (14)
Chemotherapy for resectable and advanced pancreatic cancer. (2001) (14)
The role of Notch3 signaling pathway in pancreatic cancer (2007) (14)
The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 (2013) (14)
Aflibercept (2013) (14)
Beyond exon 2--the developing story of RAS mutations in colorectal cancer. (2013) (13)
LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival (2021) (13)
A Phase II Trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma (2005) (13)
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. (2008) (13)
In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous (2017) (13)
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. (2013) (13)
Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery. (2004) (12)
Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC). (2010) (12)
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer (2016) (12)
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine (2012) (12)
Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer. (2021) (12)
Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) (2016) (12)
Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study (2013) (11)
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. (2020) (11)
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (2018) (11)
Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. (2015) (11)
451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST). (2014) (11)
Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy. (1998) (11)
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer (2017) (11)
Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? (2017) (11)
Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies (2014) (10)
Ethics in oncology: consulting for the investment industry. (2007) (10)
Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). (1999) (10)
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study (2016) (10)
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (2022) (10)
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 (2021) (10)
A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. (2011) (10)
Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer. (2017) (10)
385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results (2020) (10)
A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study. (2015) (10)
Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily × 7 every 3 weeks. (2004) (10)
Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy. (2019) (10)
First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer (2021) (10)
Past and future of pancreas cancer: are we ready to move forward together? (2008) (10)
SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset (2021) (10)
Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region. (2020) (10)
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. (2005) (9)
Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC (2016) (9)
Larotrectinib efficacy and safety in adult TRK fusion cancer patients. (2019) (9)
Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set. (2020) (9)
Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery (2004) (9)
Mismatch Repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer. (2021) (9)
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer (2014) (8)
Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer (2006) (8)
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS (2017) (8)
A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. (2008) (8)
374PDA first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL (2017) (8)
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma (2022) (8)
PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study. (2021) (8)
Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily x 3 schedule (2008) (8)
Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific? (2003) (8)
Faculty Opinions recommendation of Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). (2020) (8)
Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors (2020) (7)
A 17 Year-Old Man with an Exon 11 Mutation of CD-117 Causing a Gastrointestinal Stromal Tumor (2008) (7)
Cetuximab-related hypersensitivity reactions associated with pre-existing cetuximab-specific IgE antibody (2007) (7)
Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I study. (2014) (7)
Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. (2018) (7)
Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer (2022) (7)
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers (2016) (7)
The Past, Present, and Future of Pancreatic Cancer Clinical Trials. (2016) (7)
A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. (2004) (7)
Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor (2019) (7)
Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132). (2016) (6)
Bortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlates (2008) (6)
Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic adenocarcinoma of the pancreas (MPC). (2006) (6)
Phase I trial of chemoradiation with capecitabine and vorinostat in pancreatic cancer. (2013) (6)
Intervention Protocol for Investigating Yoga Implemented During Chemotherapy. (2016) (6)
Unusually high rates of hypersensitivity to cetuximab in the middle-southern United States: Association with atopic phenotype (2007) (6)
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. (2021) (6)
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC). (2013) (6)
Pilot study to test safety and efficacy of avelumab in small bowel adenocarcinoma (SBA). (2020) (5)
A Phase I Trial of Irinotecan Alternating With Epirubicin in Patients With Advanced Malignancies (2008) (5)
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. (2019) (5)
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors. (2014) (5)
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference (2009) (5)
A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC). (2014) (5)
SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase (2019) (5)
Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience. (2015) (5)
Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results. (2016) (5)
Neuroendocrine tumors. (2019) (5)
Abstract A1: Phase 1 study of PF-03446962, a fully human mAb against activin receptor-like kinase 1 (ALK 1), a TGFβ receptor involved in tumor angiogenesis. (2011) (4)
DRAFT FOR PUBLIC COMMENT Defining Clinically Meaningful Outcomes: ASCO Recommendations to Raise the Bar for Clinical Trials (2013) (4)
An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. (2019) (4)
Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine. (2015) (4)
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies (2022) (4)
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020 (2021) (4)
Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer. (2017) (4)
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study (2022) (4)
CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results. (2019) (4)
Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy. (2002) (4)
Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients. (2018) (4)
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma (2004) (4)
Phase I Study of Eniluracil, Oral 5-Fluororacil and Gemcitabine in Patients with Advanced Malignancy (2002) (4)
Update on adjuvant trials for pancreatic cancer. (2010) (4)
New directions in the treatment of advanced colorectal cancer. (2001) (4)
Abstract CT065: Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results (2016) (3)
A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer. (2019) (3)
Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study (2009) (3)
Abstract2111: ECOG 1200: A Randomized Phase II Trial of Gemcitabine Plus Radiotherapy vs Gemcitabine, 5-Fluorouracil and Cisplatin Followed by Radiotherapy and 5-Fluorouracil in Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma (2006) (3)
Abstract CT199: Larotrectinib in TRK fusion cancer patients: Outcomes by prior therapy and performance status (2020) (3)
Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses (2019) (3)
Peritoneal Carcinomatosis in Well-Differentiated Small-Intestinal Neuroendocrine Tumors with Mesenteric Tumor Deposits. (2019) (3)
First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors (2018) (3)
Evaluation of determinants for age disparities in the survival improvement of colon cancer: results from a cohort of more than 486,000 patients in the United States. (2020) (3)
KRN330, a fully human antibody against A33, in combination with irinotecan for patients with metastatic colorectal cancer (mCRC). (2011) (3)
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy. (2021) (3)
Clinical and molecular markers of immune checkpoint inhibitor (ICI) response in dMMR colorectal cancer (CRC) patients (pts). (2020) (3)
Abstract CT064: Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience (2016) (3)
The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona (2014) (3)
Racial/Ethnic Disparities in Mortality Related to Access to Care for Major Cancers in the United States (2022) (3)
Adjuvant therapy for pancreatic cancer: to treat or not to treat? (2007) (3)
Abstract 2431: In vivo antibody binding to tumor in xenograft rodent models and colorectal cancer patients treated with anti-A33 antibody KRN330 (2010) (3)
Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. (2018) (3)
Phase Ib study of gemcitabine and oxaliplatin with erlotinib in patients with advanced biliary tract cancer. (2012) (3)
Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC). (2018) (3)
Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement. (2022) (3)
Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. (2019) (3)
A multicenter study of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors. (2018) (3)
Faculty Opinions recommendation of Strategies in developing immunotherapy for pancreatic cancer: recognizing and correcting multiple immune "defects" in the tumor microenvironment. (2020) (3)
Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience (2018) (2)
535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer (2021) (2)
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy (2022) (2)
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. (2005) (2)
Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial. (2020) (2)
When is Treatment for Cancer Economically Justified? (1990) (2)
Liver Metastases of Small Intestine Neuroendocrine Tumors: Ki67 heterogeneity and WHO grade discordance with primary tumors (2015) (2)
Second-line therapy in colorectal cancer. (2000) (2)
Abstract P4-22-15: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results (2017) (2)
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (2019) (2)
Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis. (2012) (2)
A phase IB study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: An Academic GI Cancer Consortium (AGICC) study. (2012) (2)
Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children. (2014) (2)
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial (2022) (2)
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer. (2019) (2)
Phase II trial of sorafenib (S) and erlotinib (E) in unresectable pancreas cancer (UPC): Final results and correlative findings. (2013) (2)
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer (2008) (2)
Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. (2022) (2)
Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results (2015) (2)
Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population. (2020) (2)
SO-31 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset (2022) (1)
Management of Patients With Pancreatic Cancer Using the "Right Track" Model. (2023) (1)
Stereotactic Radiosurgery in the Treatment of Brain Metastases from Colorectal Cancer: Should Patients be Treated with Up-front Whole-brain Radiotherapy? (2010) (1)
3019 POSTER Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy (2007) (1)
Phase II clinical trial of novel agent PBI-05204 in patients with metastatic pancreatic adenocarcinoma (mPDA). (2020) (1)
Faculty Opinions recommendation of Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. (2020) (1)
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302). (2021) (1)
464P Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study) (2020) (1)
Complete response to neoadjuvant chemoradiation therapy for esophageal cancer does not confer a survival advantage (2004) (1)
Academic Cancer Center Phase I Program Development (2017) (1)
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) (2023) (1)
Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer. (2017) (1)
Abstract C059: Inhibition of thymidylate synthase by the ProTide NUC-3373:in vitroanalysis and clinical validation (2019) (1)
342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study (2021) (1)
975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma (2020) (1)
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer (2012) (1)
Safety and Ef ﬁ cacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study (2020) (1)
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors. (2019) (1)
Intervention Protocol for Investigating Yoga Implemented During Chemotherapy. (2016) (1)
Efficacy and safety of panitumumab across five clinical studies in patients with metatastic colorectal cancer. (2007) (1)
Racial disparity in taxane‐induced neutropenia among cancer patients (2021) (1)
A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659). (2018) (1)
BRAF mutations in colonic high-grade neuroendocrine carcinoma. (2016) (1)
Routine multiplexed mutational analysis of colorectal cancers (CRCs): A single-institution experience. (2015) (1)
Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors (2017) (1)
354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302) (2022) (1)
A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin ( PNU-166196 A ) , a Novel DNA Minor Groove Binder , in Adult Patients with Advanced Solid Tumors (2004) (1)
Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer. (2018) (1)
A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate. (2021) (1)
A Phase I Study of Neoadjuvant Cyclooxygenase-2 Inhibition and Chemoradiation for Stage II/III Rectal Cancer (2007) (0)
Safety and efficacy of combination of temozolomide and pazopanib in patients with advanced pancreatic neuroendocrine tumors (PNET). (2016) (0)
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours (2018) (0)
NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment. (2018) (0)
A phase I trial of an anti-pka oligonucleotide (GEM231) administered with weekly CPT-11 (2004) (0)
Faculty Opinions recommendation of Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. (2020) (0)
A phase 1b/2 study of ibrutinib combination therapy in selected advanced genitourinary and gastrointestinal tumors. (2016) (0)
463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up (2022) (0)
Efficacy and safety profile of antivascular endothelial growth factor receptor tyrosine kinase inhibitors (avRTKIs) in patients (Pts) with neuroendocrine tumors(NETs): A systematic review and meta-analysis (SRMA). (2022) (0)
Faculty Opinions recommendation of Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. (2020) (0)
Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. (2021) (0)
Berzosertib. ATR kinase inhibitor, Treatment of solid tumors (2019) (0)
Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer. (2018) (0)
Pancreatic AdenocarcinomaPractice Guidelines in Oncology (2010) (0)
A phase I study of neoadjuvant paclitaxel/radiation in patients with potentially resectable adenocarcinoma of the pancreas (2007) (0)
234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3 in patients with advanced solid tumors (2010) (0)
Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. (2023) (0)
Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study (2023) (0)
Novel PET/CT imaging biomarkers of CB-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory RAS wildtype (WT) colorectal cancer: A phase I/II study. (2018) (0)
Cancers of the Pancreas Update 2023. (2023) (0)
A phase I trial of an anti-pka oligonucleotide (GEM231) administered with weekly CPT-11. (2004) (0)
Preliminary results of a phase II study of cyclooxygenase-2 (COX-2) inhibition in rectal cancer (2004) (0)
Faculty Opinions recommendation of Pancreatic cancer genomes: implications for clinical management and therapeutic development. (2020) (0)
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE) (2023) (0)
Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate. (0)
Current and future strategies for treating metastatic pancreatic cancer. (2004) (0)
Faculty Opinions recommendation of Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. (2020) (0)
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (2022) (0)
QIM22-197: Protected Time and Provision of Resources at National Comprehensive Cancer Network (NCCN) Member Institutions (MIs) (2022) (0)
NCCN Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology (2010) (0)
Oncology volume assessment program: Novel approach to determine patient volumes at Vanderbilt-Ingram Cancer Center (VICC) and Vanderbilt University Medical Center (VUMC). (2020) (0)
Occurrence of Oral Cancer Information in U.S State Cancer Control Plans (2008) (0)
Controversies in the adjuvant treatment of pancreas cancer: a lack of knowledge or simply a lack of will? (2007) (0)
A phase I study of DENSPM (N1, N11-diethylnorspermine) in patients with advanced hepatocellular carcinoma (HCC). (2013) (0)
Faculty Opinions recommendation of Cancer statistics, 2019. (2020) (0)
ROLE OF ADJUVANT CHEMOTHERAPY IN COLORECTAL HEPATIC METASTASIS TREATMENT (2006) (0)
Role of octreotide in pancreatic cancer (2002) (0)
Faculty Opinions recommendation of NCCN guidelines updates: pancreatic cancer. (2020) (0)
534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status (2021) (0)
RANDOMIZED TRIAL OF THREE CHEMOTHERAPY REGIMENS FOR ADVANCED COLORECTAL CANCER (2002) (0)
Patient satisfaction with placement of implantable venous access devices. (2011) (0)
Abstract CT094: Phase I study of fibroblast growth factor receptor 2 antibody-drug conjugate (FGFR2-ADC) BAY 1187982 in patients with advanced cancer (2017) (0)
Adenocarcinoma Ex goblet cell: A retrospective experience. (2018) (0)
Phase I and Pharmacokinetic Study of a Micronized Formulation of Carboxyamidotriazole , a Calcium Signal Transduction Inhibitor : Toxicity , Bioavailability and the Effect of Food 1 (2002) (0)
Faculty Opinions recommendation of Checkpoint inhibitors in pancreatic cancer. (2020) (0)
A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) [NCT03641313]. (2019) (0)
Faculty Opinions recommendation of Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. (2020) (0)
297 POSTER Phase I and pharmacokinetic trial of SJG-136 administered on a daily × 5 schedule (2006) (0)
A phase I multicenter study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET). (2015) (0)
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (2018) (0)
The Pharmacokinetics and Safety of ABT-751 , a Novel , Orally Bioavailable SulfonamideAntimitotic Agent : Results of a Phase 1 Study (2006) (0)
Neuroendocrine Carcinoma in an Adolescent With Hypercortisolemia (2012) (0)
Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis. (2023) (0)
Peritoneal carcinomatosis (PC) in well differentiated small intestinal neuroendocrine tumors (SI-NET). (2018) (0)
Advanced biliary tract cancers. (2012) (0)
Immunotherapy After Immunotherapy: Response Rescue in a Microsatellite Instability-High Colorectal Cancer Patient Post-Pembrolizumab (2020) (0)
Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma (2023) (0)
Faculty Opinions recommendation of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (2020) (0)
Combination Therapy for Liver Metastases: Chemotherapy and Radiologic Interventions (2013) (0)
1075 : A Phase II Trial of Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Resectable or Unresectable Non-Metastatic Pancreatic Cancer (2006) (0)
Abstract CT140: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer (2021) (0)
Uncommon Cancers of the Stomach (2006) (0)
Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). (2022) (0)
Analysis of BRAF and KRAS mutations in colorectal cancer and rectal carcinogenesis via fluorescent allele-specific PCR. (2011) (0)
Pancytopenia in a Patient With Metastatic Well-Differentiated Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy. (2021) (0)
Pharmacokinetic modeling and simulation (PK M&S) supported dose escalation of PF-03446962, a monoclonal antibody (mAb) against activin receptor like kinase 1, in patients with solid tumors. (2012) (0)
A Phase 1 study of ARRY-543, a potent, selective, reversible inhibitor of ErbB receptors (2007) (0)
Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). (2023) (0)
Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer. (2023) (0)
Intervention Protocol for Investigating Yoga Implemented During Chemotherapy. (2016) (0)
Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer (2015) (0)
Abstract 1310: Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients (2011) (0)
Subject Index Vol. 78, 2010 (2010) (0)
KRAS mutational status is associated with clinical response in patients with metastatic colorectal cancer receiving panitumumab monotherapy (2007) (0)
A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC). (2018) (0)
Drugs on the Horizon for Colorectal Cancer (2011) (0)
Consensus statement on mandatory measurements in Pancreatic cancer trials for systemic treatment of unresectable disease (COMMPACT) (2017) (0)
Faculty Opinions recommendation of FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. (2020) (0)
Faculty Opinions recommendation of HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. (2020) (0)
Abstract 4260: Molecular imaging of glutamine (Gln) metabolism in RAS wildtype (WT) metastatic colorectal cancer (mCRC) (2020) (0)
Faculty Opinions recommendation of Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. (2020) (0)
Faculty Opinions recommendation of Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. (2020) (0)
Efficacy and Toxicity of Anti-Vascular Endothelial Growth Receptor Tyrosine Kinase Inhibitors in Patients with Neuroendocrine Tumors – A Systematic Review and Meta-Analysis (2023) (0)
Unusual Cancers of the Pancreas (2012) (0)
Abstract CT249: A study to evaluate the safety and tolerability of the covalent phosphoinositide-3-kinase (PI3K)-alpha Inhibitor, TOS-358, in adult subjects with select solid tumors (2023) (0)
Neuroendocrine TumorsPractice Guidelines in Oncology (2012) (0)
475P A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302) (2021) (0)
Diagnosis and treatment of cholangiocarcinoma. (2004) (0)
Phase I study of gemcitabine (G), dasatinib (D), and erlotinib (E) in advanced pancreatic carcinoma (PC). (2017) (0)
Contents Vol. 78, 2010 (2010) (0)
A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance). (2018) (0)
NuTide: 302—A phase Ib study of the ProTide NUC-3373 in combination with standard therapies in advanced colorectal cancer. (2020) (0)
Abstract CT062: A phase I dose escalation study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced gastrointestinal (GI) tumors (2018) (0)
Abstract 4461: Analysis of circulating tumor DNA (ctDNA) identifies on-treatment genomic alterations in a phase 2 study of veliparib plus FOLFIRI ± bevacizumab vs. placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer (mCRC) (2019) (0)
Validating enhancer signature classifications (ESCs) in pancreatic neuroendocrine tumors (PNETs). (2020) (0)
Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns. (2020) (0)
A phase I study of veliparib (ABT-888) in combination with capecitabine (C) and temozolomide (T) in patients (pts) with advanced well-differentiated unresectable neuroendocrine tumors (wdNET). (2016) (0)
A phase II study of enterade in neuroendocrine tumor (NET) patients with quality-of-life limiting bowel movement frequency. (2020) (0)
reatment for Pancreatic Cancer : Current Therapy and ontinued Progress (0)
746PCOnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT) (2017) (0)
717 Interim clinical update of the phase 1b trial of ATRC-101 as monotherapy or in combination with pembrolizumab for select advanced solid tumors (2022) (0)
Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study. (2019) (0)
Phase II study of the clinical and biological activity of cetuximab and celecoxib in patients (pts) with refractory colorectal cancer (CRC) (2007) (0)
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (2018) (0)
Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer. (2018) (0)
Peritoneal carcinomatosis (PC) in well-differentiated (WD) small-intestinal neuroendocrine tumor (SI-NET) patients (Pts) with mesenteric tumor deposits (MTDs). (2019) (0)
CCR Drug Updates A fl ibercept (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jordan D. Berlin?

Jordan D. Berlin is affiliated with the following schools:

Harvard University
Ghent University
Autonomous University of Barcelona
University of Oxford
University of California, Los Angeles
Vanderbilt University
Stanford University
Georgetown University
University of Glasgow
Johns Hopkins University